

UC Irvine

UC Irvine Previously Published Works

Title

Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study

Permalink

<https://escholarship.org/uc/item/73f8n698>

Journal

Human Molecular Genetics, 18(12)

ISSN

0964-6906

Authors

Song, Honglin
Ramus, Susan J
Kjaer, Susanne Krüger
[et al.](#)

Publication Date

2009-06-15

DOI

10.1093/hmg/ddp138

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study

Honglin Song^{1,*}, Susan J. Ramus², Susanne Krüger Kjaer³, Richard A. DiCioccio⁴, Georgia Chenevix-Trench⁵, Celeste Leigh Pearce⁶, Estrid Hogdall³, Alice S. Whittemore⁷, Valerie McGuire⁷, Claus Hogdall⁸, Jan Blaakaer⁹, Anna H. Wu⁶, David J. Van Den Berg⁶, Daniel O. Stram⁶, Usha Menon², Aleksandra Gentry-Maharaj², Ian J. Jacobs², Penny M. Webb⁵, Jonathan Beesley⁵, Xiaoqing Chen⁵, the Australian Cancer (Ovarian) Study, The Australian Ovarian Cancer Study Group, Mary Anne Rossing¹⁰, Jennifer A. Doherty¹⁰, Jenny Chang-Claude¹¹, Shan Wang-Gohrke¹², Marc T. Goodman¹³, Galina Lurie¹³, Pamela J. Thompson¹³, Michael E. Carney¹³, Roberta B. Ness¹⁴, Kirsten Moysich¹⁵, Ellen L. Goode¹⁶, Robert A. Vierkant¹⁶, Julie M. Cunningham¹⁶, Stephanie Anderson¹⁶, Joellen M. Schildkraut¹⁷, Andrew Berchuck¹⁷, Edwin S. Iversen^{17,18}, Patricia G. Moorman¹⁷, Montserrat Garcia-Closas¹⁹, Stephen Chanock¹⁹, Jolanta Lissowska²⁰, Louise Brinton¹⁹, Hoda Anton-Culver²¹, Argyrios Ziogas²¹, Wendy R. Brewster²², Bruce A.J. Ponder¹, Douglas F. Easton²³, Simon A. Gayther² and Paul D.P. Pharoah¹ on behalf of the Ovarian Cancer Association Consortium (OCAC)

¹CR-UK Department of Oncology, Strangeways Research Laboratory, University of Cambridge, Cambridge, UK, ²Gynaecological Oncology Unit, UCL EGA Institute for Women's Health, University College London, UK, ³Department of Viruses, Hormones and Cancer, Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark, ⁴Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, NY, USA, ⁵The Queensland Institute of Medical Research, Post Office Royal Brisbane Hospital, Australia, ⁶Keck School of Medicine, University of Southern California, Los Angeles, CA, USA, ⁷Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA, USA, ⁸Gynaecologic Clinic, The Juliane Marie Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, ⁹Department of Gynaecological and Obstetrics, Skejby University Hospital, Århus, Denmark, ¹⁰Program in Epidemiology, Fred Hutchinson Cancer Research Centre, Seattle, WA, USA, ¹¹Division of Cancer Epidemiology, German Cancer Research Centre, Heidelberg, Germany, ¹²Department of Obstetrics and Gynaecology, University of Ulm, Ulm, Germany, ¹³Epidemiology Program, Cancer Research Centre of Hawaii, University of Hawaii, Honolulu, HI, USA, ¹⁴School of Public Health, The University of Texas, Houston, TX, USA, ¹⁵Roswell Park Cancer Centre, Buffalo, NY, USA, ¹⁶Mayo Clinic College of Medicine, Rochester, MN, USA, ¹⁷The Comprehensive Cancer Centre, Duke University Medical Centre, Durham, NC, USA, ¹⁸Department of Statistical Science, Duke University, Durham, NC, USA, ¹⁹Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA, ²⁰Department of Cancer Epidemiology and Prevention, M. Skłodowska-Curie Institute of Oncology and Cancer Centre, Warsaw, Poland, ²¹Department of Epidemiology, University of California, Irvine, CA, USA, ²²Department of OB/GYN, School of Medicine, University of North Carolina, Chapel Hill, CA NC27599-7570, USA and ²³CR-UK Genetic Epidemiology Unit, Strangeways Research Laboratory, University of Cambridge, Cambridge, UK

Received January 13, 2009; Revised March 11, 2009; Accepted March 18, 2009

*To whom correspondence should be addressed. Tel: +44 1223740161; Fax: +44 1223740147; Email: honglin@sr1.cam.ac.uk

Because both ovarian and breast cancer are hormone-related and are known to have some predisposition genes in common, we evaluated 11 of the most significant hits (six with confirmed associations with breast cancer) from the breast cancer genome-wide association study for association with invasive ovarian cancer. Eleven SNPs were initially genotyped in 2927 invasive ovarian cancer cases and 4143 controls from six ovarian cancer case–control studies. Genotype frequencies in cases and controls were compared using a likelihood ratio test in a logistic regression model stratified by study. Initially, three SNPs (rs2107425 in *MRPL23*, rs7313833 in *PTHLH*, rs3803662 in *TNRC9*) were weakly associated with ovarian cancer risk and one SNP (rs4954956 in *NXPH2*) was associated with serous ovarian cancer in non-Hispanic white subjects (P -trend < 0.1). These four SNPs were then genotyped in an additional 4060 cases and 6308 controls from eight independent studies. Only rs4954956 was significantly associated with ovarian cancer risk both in the replication study and in combined analyses. This association was stronger for the serous histological subtype [per minor allele odds ratio (OR) 1.07 95% CI 1.01–1.13, P -trend = 0.02 for all types of ovarian cancer and OR 1.14 95% CI 1.07–1.22, P -trend = 0.00017 for serous ovarian cancer]. In conclusion, we found that rs4954956 was associated with increased ovarian cancer risk, particularly for serous ovarian cancer. However, none of the six confirmed breast cancer susceptibility variants we tested was associated with ovarian cancer risk. Further work will be needed to identify the causal variant associated with rs4954956 or elucidate its function.

INTRODUCTION

Recent advances in high-throughput genotyping technologies have enabled rapid and efficient genotyping to be performed for hundreds of thousands of genetic variants without prior knowledge of gene function as part of genome-wide association studies (GWAS). Several GWAS have led to the identification of novel loci for many different common complex diseases, including diabetes, Crohn's disease, rheumatoid arthritis and breast, prostate and colorectal cancers, confirming that susceptibility to these diseases has a polygenic component (1–4). The known ovarian cancer susceptibility genes, such as *BRCA1* and *BRCA2*, appear to explain <40% of the excess familial risk of this disease (5). It is likely that a combination of multiple low or moderate penetrance genetic variants contribute to the remaining unexplained excess ovarian cancer risks. It is evident that some loci regulate carcinogenic pathways common to multiple cancers, for example, the variant rs6983267 in 8q24 is associated with colorectal, prostate and ovarian cancer risk (6). Also, *BRCAC1* and *BRCA2* gene mutations are associated with the variation in the risks of both breast and ovarian cancers. The development of breast and ovarian cancers both have a hormonal basis of female cancers, therefore, it seems logical to hypothesize that these malignancies share some common genetic risks and that breast cancer susceptibility loci may also be associated with the risk of ovarian cancer.

The aim of this study is to evaluate whether the 11 SNPs that were most strongly associated with breast cancer risk in our breast cancer GWAS (7) were associated with epithelial ovarian cancer (EOC) risk in 14 case–control studies which comprised 6987 invasive EOC cases and 10451 controls. This represents the largest ovarian cancer case–control analysis conducted to date. These 11 SNPs included six breast cancer susceptibility variants that reach genome-wide significance ($P < 10^{-8}$) [i.e. rs2981582 (*FGFR2*), rs12443621 (*TNRC9*), rs13281615 (8q), rs3817198 (*LSPI*), rs3803662 (*TNRC9*) and rs889312 (*MAP3K1*)]. The remaining five top hits from breast cancer GWAS, namely rs4666451 (located on chromosome 2p), rs2107425 (*MRPL23*), rs7313833

(*PTHLH*), rs981782 (on chromosome 5p) and rs4954956 (*NXPH2*) are also strong candidate for breast cancer associations ($P < 10^{-5}$).

RESULTS

We have genotyped the 11 SNPs identified through our GWAS for breast cancer in a set of six ovarian cancer case–control studies. Genotype distributions in controls were consistent with Hardy–Weinberg equilibrium (HWE) except for rs4666451 in the USC ($P = 0.02$) and UKO study

($P = 0.01$) and rs7313833 in the AUS study ($P = 0.04$). These deviations are likely to be due to chance, rather than a reflection of poor genotyping, because inspection of the cluster plots indicated good discrimination between genotype; furthermore deviation from HWE was not observed in cases. In addition, the genotyping for rs981782 failed in the UKO study and rs7313833 failed in the GER study.

Genotype-specific odds ratios (ORs) and tests of association are presented in Table 1. The genotype-specific risks for serous ovarian cancer, estimated from the combined data, are also presented in Table 1. The observed genotype frequencies for each of the data sets are presented in Supplementary Material, Table S1. There was no association in controls between age and genotype frequency for any of the SNPs and age-adjusted genotype-specific risks were similar to the unadjusted ORs (data not shown). Two SNPs (rs7313833 and rs210742) showed some evidence of association with all types of invasive ovarian cancer, whereas rs4954956 and rs210742 showed some evidence of association with serous type ovarian. The association of rs3803662 with ovarian cancer risk was of borderline significance ($P = 0.07$) with ovarian cancer risks. There was no association for the remaining seven SNPs ($P > 0.1$).

Carriers of the minor allele of rs7313833 were at increased risk of ovarian cancer: per minor allele OR = 1.09, 95% CI 1.01–1.18, P -trend = 0.027. Carriers of the minor allele of rs2107425 were at decreased risk of ovarian cancer overall and serous type ovarian cancer: per minor allele OR = 0.91

Table 1. Genotype-specific risks (95% CI) for all types of invasive ovarian cancer and serous type ovarian cancer

SNP	Gene/ region	MAF	No. controls	Reported breast cancer, OR (95% CI) ^a	All type of invasive cases				Serous type invasive cases			
					No. cases	<i>P</i> -het ^b	<i>P</i> -trend	OR (95% CI) ^c	No. serous	<i>P</i> -het ^b	<i>P</i> -trend	OR (95% CI) ^c
rs2981582	<i>FGFR2</i>	0.39	3903	1.26 (1.23–1.30)	2513	0.09	0.46	0.97 (0.90–1.05)	1340	0.24	0.82	0.99 (0.90–1.08)
rs12443621	<i>TNRC9</i>	0.46	3860	1.11 (1.08–1.14)	2464	0.27	0.24	0.96 (0.89–1.03)	1309	0.67	0.53	0.97 (0.89–1.06)
rs13281615	8q	0.40	3892	1.08 (1.05–1.11)	2502	0.85	0.69	0.99 (0.92–1.06)	1331	0.86	0.58	0.97 (0.89–1.07)
rs3817198	<i>LSP1</i>	0.31	3795	1.07 (1.04–1.11)	2479	0.71	0.75	1.01 (0.94–1.09)	1319	0.60	0.94	1.00 (0.90–1.10)
rs889312	<i>MAP3K1</i>	0.28	3897	1.13 (1.10–1.16)	2513	0.93	0.80	1.01 (0.93–1.09)	1336	0.94	0.91	0.99 (0.90–1.10)
rs4666451	2p	0.40	3871	0.97 (0.94–1.00)	2488	0.78	0.55	1.02 (0.95–1.10)	1324	0.83	0.57	1.03 (0.94–1.12)
rs2107425	<i>MRPL23</i>	0.32	3891	0.96 (0.93–0.99)	2504	0.01	0.015	0.91 (0.84–0.98)	1335	0.008	0.048	0.91 (0.82–1.00)
rs7313833	<i>PTHLH</i>	0.33	3865	1.03 (1.00–1.06)	2483	0.06	0.027	1.09 (1.01–1.18)	1327	0.72	0.60	1.03 (0.94–1.13)
rs981782	5p	0.47	3657	0.96 (0.93–0.99)	2396	0.55	0.31	1.04 (0.97–1.12)	1279	0.63	0.35	1.04 (0.95–1.14)
rs4954956	<i>NXPH2</i>	0.25	3913	0.97 (0.94–1.00)	2497	0.79	0.50	1.03 (0.95–1.12)	1325	0.13	0.049	1.11 (1.00–1.23)
rs3803662	<i>TNRC9</i>	0.27	3889	1.20 (1.16–1.24)	2527	0.14	0.07	0.92 (0.84–1.01)	1335	0.11	0.10	0.92 (0.83–1.02)

The combined data from the initial stage1 studies of White non-Hispanic subjects. The following studies are included in the initial studies: AUS, SEA, MAL, STA, UKO and USC.

^aReported breast cancer GWAS per allele odds ratio (OR) and 95% CI (7).

^bComparison of genotype frequency between cases and controls (2df).

^cPer allele odds ratio and 95% CI, data highlighted with bold text are borderline significant ($P < 0.1$) results.

Table 2. Genotype-specific risks 95% CI for all types and serous type of invasive epithelial ovarian cancer in the validation (stage 2) studies for non-Hispanic White subjects

SNP	Gene/region	No. controls	Validation studies without initial six studies				All studies combined				
			No. cases	<i>P</i> -het ^a	<i>P</i> -trend	OR (95% CI) ^b	No. controls	No. cases	<i>P</i> -het ^a	<i>P</i> -trend	OR (95% CI) ^b
All types of invasive ovarian cancer											
rs2107425	<i>MRPL23</i>	4647	2862	0.22	0.21	1.05 (0.97–1.12)	8538	5366	0.07	0.49	0.98 (0.93–1.03)
rs7313833	<i>PTHLH</i>	4575	2896	0.71	0.61	0.98 (0.91–1.05)	8440	5379	0.31	0.22	1.03 (0.98–1.09)
rs4954956	<i>NXPH2</i>	4540	2856	0.03	0.01	1.10 (1.02–1.19)	8453	5353	0.05	0.02	1.07 (1.01–1.13)
rs3803662	<i>TNRC9</i>	5084	3121	0.40	0.82	1.01 (0.94–1.08)	8973	5648	0.54	0.32	0.97 (0.92–1.03)
Serous type ovarian cancer											
rs2107425	<i>MRPL23</i>	4647	1611	0.12	0.06	1.09 (1.00–1.19)	8538	2946	0.06	0.91	1.00 (0.94–1.07)
rs7313833	<i>PTHLH</i>	4575	1648	0.35	0.17	0.94 (0.86–1.03)	8440	2975	0.72	0.55	0.98 (0.92–1.04)
rs4954956	<i>NXPH2</i>	4540	1602	0.003	0.001	1.17 (1.06–1.28)	8453	2927	0.0004	0.0002	1.14 (1.07–1.22)
rs3803662	<i>TNRC9</i>	5084	1780	0.44	0.18	1.06 (0.97–1.16)	8973	3115	0.57	0.96	1.00 (0.94–1.07)

The validation studies included: DOV, GER, HAW, HOP, MAY, NCO, POL and UCI. Data highlighted with bold text are significant results ($P < 0.05$).

^aComparison of genotype frequency between cases and controls (2df).

^bPer allele Odds ratio and 95% CI.

95% CI 0.84–0.98 ($P = 0.027$) and OR = 0.91 95% CI 0.82–1.00, (P -trend = 0.048), respectively. Carriers of the minor allele of rs4954956 were at increased risk of serous type ovarian cancer: per minor allele OR = 1.10 95% CI 1.02–1.19, (P -trend = 0.01).

The four SNPs (rs2107425, rs3803662, rs4954956 and rs7313833) with some evidence of association in either all cases or serous type ovarian cancer were then genotyped in the validation set. The results of the validation component alone and in combination with the initial set are presented in Table 2. SNP rs4954956 (*NXPH2*) was associated with overall ovarian cancer risk and with the risk of serous subtype both in the validation set alone and in the combined analysis, although the risk was stronger for the serous subtype (Table 2). The risk for serous ovarian cancer per minor allele of rs4954956 was 1.17 (95% CI 1.06–1.28, $P = 0.0011$) for the validation set and 1.14 (95% CI 1.07–1.22, $P = 0.00017$) for the combined analyses. For all types of ovarian cancer, per minor allele risk for rs4954956 was

1.10 (95% CI 1.02–1.19; $P = 0.01$) for the validation set and 1.07 (95% CI 1.01–1.13; $P = 0.02$) for the combined analyses. Figure 1 shows the genotype-specific ORs for each ovarian study and for the combined analysis for rs4954956. The effect of rs4954956 was slightly attenuated after adjusting for a first degree family history of breast cancer [per rare allele OR 1.06, 95% CI 0.97–1.16 ($P = 0.17$) for all types of ovarian cancer and 1.10, 95% CI 0.99–1.22 ($P = 0.066$) for serous type of ovarian cancer, respectively]. The remaining three SNPs were not validated. There was no evidence for between-study heterogeneity ($P > 0.05$) for all the SNPs tested except rs3817198 ($P = 0.0002$) in the initial set.

DISCUSSION

This is the largest ovarian cancer association study conducted to date involving 14 studies from Ovarian Cancer Association Consortium (OCAC) and comprising 5876 invasive EOC




Figure 1. Genotype-specific risks of SNP rs4954956 for ovarian cancer by study in White non-Hispanic subjects. (A) All ovarian cancer subtypes included. (B) Analysis restricted to serous type ovarian cancers.

cases and 9273 controls of non-Hispanic origin. We observed an association for the minor allele of SNP rs4954956 with increased risks of EOC both in the initial set and in the replication set with the strongest gene-dose effect for serous type EOC. We urge caution in the interpretation of these results as a number of reported positive associations in the literature

have not been replicated by the subsequent studies. Indeed, the proportion of studies with false-positive findings can be as high as 95% in association studies between genetic variants and disease risks (8–10). To estimate the likelihood that our results represent a true association with ovarian cancer risks, we calculated the false-positive report probability (FPRP)

Table 3. False-positive report probability values for rs4954956

SNP	Cancer type	OR 95% CI	Statistical power ^a	P-value (α)	Prior probability				
					0.25	0.1	0.01	0.001	0.0001
rs4954956	Ovarian	1.07 (1.01–1.13)	0.53	0.02	0.083	0.21	0.75	0.97	0.997
rs4954956	Serous ovarian	1.14 (1.07–1.22)	0.53	0.00017	0.001	0.003	0.029	0.23	0.75

Data highlighted with bold text are false-positive report probability (FPRP) <0.5.

^aUsing co-dominant model.

under different prior probability scenarios (11). The FPRP depends on the prior probability that a true association exists, the observed level of significance (α) and the statistical power to detect the OR of the alternative hypothesis at the given α . As there are a large number of common SNPs in the genome, the overall prior probability of association is very low (<1 in 10^6). However, the prior probability that rs4954956 is associated with ovarian cancer is more favourable as this is one of the best candidates from our breast cancer GWAS and therefore a good candidate for ovarian cancer susceptibility. The FPRPs for rs4954956 under various prior probabilities and the power to detect the association at our observed significance level α (assuming the true effect size is equal to that observed) are presented in Table 3. For example, assuming the prior probability to be 1 in 100 or 1 in 1000, the FPRP for association of rs4954956 with serous ovarian cancer would be 0.03 and 0.23, respectively. This, along with the fact that results were indeed independently replicated in the case–control validation studies (Table 2), suggests that this association is robust (Table 3). The evidence, however, is weaker for its association with all types of ovarian cancer under the same prior probabilities.

Underlying population stratification is another explanation for a spurious association. This occurs when allele frequencies differ between population subgroups and cases and controls are drawn differentially from those subgroups. To minimize the impact of population stratification, analyses were restricted to White subjects with non-Hispanic origin. If population stratification were present, it is unlikely that the same degree of stratification would be found in all 14 studies. We did not observe any heterogeneity between different studies in the initial or replication studies or the combined analysis for rs4954956, thus providing evidence against substantial population stratification or other study-specific biases.

If the observed association is confirmed, the SNP may be directly causal or an indirect marker in linkage disequilibrium with the real cause of malignancy. SNP rs4954956 is in an intergenic region situated <7 kb upstream of the gene *NXPH2*, which encodes the protein neurexophilin 2. *NXPH2* is expressed in kidney and brain and acts as a signalling molecule; it has also been shown to be expressed in the ovary (<http://www.genecards.org/>). It is a signalling molecule that resembles neuropeptides and acts by binding to alpha-neurexins and possibly other receptors (12). However, it is not known whether rs4954956 directly affects *NXPH2* gene expression: rs4954956 is not in a highly conserved region (<http://genome.ucsc.edu/cgi-bin/hgGateway>) and various bioinformatics tools such as SNAP (<http://www.broad.mit.edu/mpg/snap>) did not reveal any variants associated with this SNP

($r^2 > 0.8$) that have a putative function. It is possible that the functional effects of rs4954956 are due to other, as yet unidentified variants that are strongly correlated with this SNP.

Although breast cancer and ovarian cancer are both hormonal related female cancers and share some common genetic risk factors such as *BRCA1/BRCA2* mutations, our data suggest that the overlap between ovarian and breast cancer susceptibility alleles is limited. We found no evidence of an association of ovarian cancer risk with the remaining 10 breast GWAS hits tested. Gates *et al.* (13) recently reported a null association for seven breast cancer susceptibility alleles in two ovarian cancer case–control populations, five of these alleles (i.e. rs2981582, rs3803662, rs889312, rs3817198 and rs13281615) were also genotyped in our study. Our meta-analysis pooling Gates *et al.*'s data together with ours for these five SNPs appears to confirm that they are not associated with ovarian cancer risks (data not shown). By combined data from 14 ovarian cancer case–control studies (5876 cases/9273 controls of non-Hispanic origin), we were able to provide at least 90% power to detect a co-dominant allele with a minor allele frequency of 0.27 that confers a relative risk of 1.1 at a Type 1 error of 0.05. However, our power to detect the alleles associated with smaller ovarian cancer risks is low, and we cannot exclude the possibility that the alleles investigated are associated with smaller risks for ovarian cancer.

In conclusion, we have found that rs4954956 is associated with an increased ovarian cancer risk, but none of the top six confirmed breast cancer susceptibility variants tested is associated with ovarian cancer. Further work will be needed to determine a functional rationale for rs4954956 or any correlated variants in causing ovarian cancer.

MATERIALS AND METHODS

Study subjects

Initial set. Six case–control studies contributed data to the initial (stage 1) analysis, including three studies from Europe (SEA, MAL and UKO), two from the USA (STA and USC), and one from Australia (AUS). Table 4 provides details for each of the studies which followed a population-based case–control design. Participation rates for cases and controls were generally excellent, and included largely White non-Hispanic women. In total, stage 1 comprised 2927 invasive ovarian cases and 4143 controls.

Validation set. Eight case–control studies contributed data to the validation set (stage 2) which included six studies from the

Table 4. Study description

Study	Study name	No. controls ^a	No. cases ^a	No. serous type cases ^a	Total subjects ^a	% White non-His	Source	Participation rate
AUS	Australian Cancer Study (ovarian cancer) AOCS	1163 (1082)	1130 (867)	731 (563)	2293 (1949)	85	Australia: population based	Case: 84% Control: 47%
DOV	DOVE, Seattle (16)	796 (724)	584 (533)	332 (303)	1380 (1257)	91	USA: population based	Case: 77% Control: 69%
GER	GOCS	433 (433)	229 (228)	107 (107)	662 (661)	100	Germany: population based	Case: 58% Control: 51%
HAW	Hawaii Ovarian Cancer Study	602(158)	300 (70)	125 (36)	902 (228)	25	Hawaii USA: population based	Case: 66% Control: 69%
HOP	HOPE study, Pittsburgh	672 (643)	300 (285)	169 (162)	972 (928)	95	USA: population based	Case: 69% Control: 81%
MAL	MALOVA, Copenhagen	1221 (1221)	446 (446)	275 (275)	1667 (1667)	100	Denmark: population based	Case: 79% Control: 67%
MAY	Mayo Clinic Rochester Minnesota	467 (440)	337 (322)	206 (199)	804 (762)	95	USA: clinic-based	Case: 84% Control: 65%
NCO	NCOCS	917 (726)	791 (616)	478 (375)	1708 (1342)	79	USA: population based	Case: 70% Control: 63%
POL	POCS, Warsaw and Lodz Poland	625 (625)	264 (264)	118 (118)	889 (889)	100	Poland: population based	Case: 71% Control: 67%
SEA	SEARCH, Cambridge, UK	1235 (1229)	1013 (947)	391 (369)	2248 (2176)	97	England: population based	Case: 67% Control: 84%
STA	GEOCS, Stanford	429 (367)	325 (287)	176 (159)	754 (654)	87	USA: population based	Case: 75% Control: 75%
UCI	UC Irvine Ovarian Cancer Study, California	536 (431)	339 (284)	183 (148)	875 (715)	82	USA: population based	Case: 70% Control: 80%
UKO	UKOPS	601 (595)	298 (288)	137 (135)	899 (883)	98	England: population based	Case: 86% Control: 97%
USC	LAC-CCOC	754 (599)	631 (439)	380 (279)	1385 (1083)	75	USA: population based	Case: 73% Control: 73%
Total	10451 (9273)	6987 (5876)	3808 (3228)	17438 (15149)	87			

AOCS, Australian Ovarian Cancer Study; DOVE, Diseases of the Ovary and their Evaluation Study; GOCS, German Ovarian Cancer Study; HOPE, hormones and ovarian cancer prediction; MALOVA, Malignant Ovarian Cancer Study; NCOCS, North Carolina Ovarian Cancer Study; POCS, Polish Ovarian Cancer Study; GEOCS, genetic epidemiology of ovarian cancer; UKOPS, United Kingdom Ovarian Cancer Population Study; LAC-CCOC, Los Angeles County Case–Control Studies of Ovarian Cancer.

^aNumbers in parentheses are the number of women who are non-Hispanic White origin.

USA (DOV, HOP, MAY, NCO, UCI, HAW) and two studies from Europe (GER, POL). Stage 2 also included additional samples from Australia (AUS) (413 cases/448 controls), UKO (180 cases/333 controls) and USC (323 cases/479 controls) studies described above. Thus, the total validation set comprised 4060 invasive ovarian cancer cases and 6308 controls (Table 4).

These 14 case–control studies from OCAC contained a total of 6987 invasive ovarian cancer cases and 10451 controls when combined. Details of all these case–control studies have been published (14,15).

To reduce the possibility of population stratification, the analyses were limited to the 5876 cases and 9273 controls who were of non-Hispanic White origin for whom genotype information was available. All studies were approved by the review boards and Ethics Committees of their parent institutions and written informed consent was obtained from all participants.

Genotyping

Genotyping was performed at 11 different centres in 384-well plate formats and all but one study (AUS) used Taqman™

7900HT Sequence Detection System according to the manufacturer's instructions. The AUS study used iPLEX technology (Sequenom) for genotyping according to the manufacturer's instructions. Genotypes were determined using Allelic Discrimination Sequence Detection Software (Applied Biosystems, Warrington, UK). Assays were carried out in 384-well plates and included at least 3% duplicate samples in each plate for quality control. The six studies in the initial set were genotyped either at the Department of Oncology, University of Cambridge or at the Gynaecological Oncology Unit, University College London. The validation studies were genotyped by the individual study centres. Each assay was carried out using 10 ng DNA in a 5 µl reaction using TaqMan universal PCR master mix, forward and reverse primers and FAM and VIC labelled probes designed by Applied Biosystems (ABI Assay-by-design). Details of primer and probe sequences and assay conditions used for each polymorphism analysed are available upon request.

Genotyping quality control. We compared genotype call rates and concordance by study and overall. We used the following criteria as a measure of acceptable genotyping: (1) >3% sample duplicates included; (2) concordance rate for

the duplicates $\geq 98\%$; (3) overall call rate (by study) $>95\%$ and (4) call rates $>90\%$ for each individual 384-well plate. The data for any SNP failing these criteria in any study were excluded from the final analyses. The HWE among White non-Hispanic controls was used to examine the quality of genotyping. For any SNP that was out of HWE ($P < 0.05$), the genotyping call rate was reviewed and the data excluded if the genotype clusters was found to be suboptimal. However, some studies with genotypes out of HWE were included if their genotypes, based on clusters, were of excellent quality. Genotyping consistency across labs was also evaluated by genotyping a common panel of CEPH-Utah trios including 90 individual DNA samples, five duplicate samples and one negative control (http://ccr.coriell.org/Sections/Search/Panel_Detail.aspx?PgId=202&Ref=HAPMAPPT01). The concordance of genotyping results between the centres was required to be $>98\%$ in order for the genotype data to be included. No attempt was made to repeat genotyping in DNA samples that did not provide a clear genotype at the first attempt resulting in variations in the number of studies/samples that were successfully genotyped for each polymorphism.

Statistics

Deviation of genotype frequencies from those expected under HWE was assessed by χ^2 tests with one degree of freedom (1df) for each study of controls as part of the genotyping quality control. The primary test of association was the comparison of genotype frequencies in cases and controls using a test for gene-dose effect for each SNP through an interval variable with three levels: 0, 1, 2; one assigned to each genotype. This was done using unconditional logistic regression stratified by study. OR for allele dosage and associated 95% CI were also estimated by unconditional logistic regression. We tested for heterogeneity between study strata by comparing logistic regression models with and without a genotype-stratum interaction term using likelihood ratio tests. A subgroup analysis was used to compare genotype-specific risks by disease subgroup with the controls. We limited subgroup analysis to the serous histology type as the number of cases diagnosed with other subtypes was low.

SUPPLEMENTARY MATERIAL

Supplementary Material is available at *HMG* online.

ACKNOWLEDGEMENT

We thank all the individuals who took part in this study. We thank: Hannah Munday, Barbara Perkins, Mitul Shah, Clare Jordan, Judy West, Anabel Simpson, Sue Irvine, Anne Stafford, the SEARCH team: the local general practices and nurses and the Eastern Cancer Registry for recruitment of the UK cases and the EPIC-Norfolk investigators for recruitment of the UK controls for SEA study; We thank all members of the research team, including research nurses, research scientists, data entry personnel and consultant gynaecological oncologists for their help in establishing the UKOPS case-control collection, particularly we thank Eva Wozniak for the efforts in genotyping and Andy Ryan and Jeremy Ford for data and sample management for UKO study. We thank Ursula Eilber and Tanja Koehler for competent technical assistance for German Ovarian Cancer study. The AOCS Management Group (D. Bowtell, G. Chenevix-Trench, A. deFazio, D. Gertig, A. Green, P. Webb) gratefully acknowledges the contribution of all the clinical and scientific collaborators (see <http://www.aocstudy.org/>). The AOCS and ACS Management Group (A. Green, P. Parsons, N. Hayward, P. Webb, D. Whiteman) thank all of the project staff, collaborating institutions and study participants. We thank all the funding agencies and institutions for their support. D.F.E. is a Principal Research Fellow of Cancer Research UK, P.D.P.P. is CRUK Senior Clinical Research Fellow. S.J.R. is supported by the Mermaid/Eve Appeal, G.C.T. and P.W. are supported by the NHMRC.

Conflict of Interest statement. None declared.

FUNDING

This work was supported by Cancer Research UK, The Roswell Park Alliance, The Danish Cancer Society and The National Cancer Institute (CA71766, CA16056, RO1 CA61107 and RO1 CA122443). We are grateful to the family and friends of Kathryn Sladek Smith for their generous support of OCAC through their donations to the Ovarian Cancer Research Fund. US Army Medical Research and Materiel Command under DAMD17-01-1-0729, the Cancer Council Tasmania and Cancer Foundation of Western Australia (AOCS study), The National Health and Medical Research Council of Australia (199600) (ACS study). DOV study was supported by the US national Cancer Institute grants R01 CA87538 and R01 CA112523. The German Ovarian Cancer Study was supported by the German Federal Ministry of Education and Research of Germany, Programme of Clinical Biomedical Research grant 01 GB 9401 and the genotyping in part by the state of Baden-Württemberg through Medical Faculty of the University of Ulm (P.685). HAW study was supported by US Public Health Service grant R01-CA- 58598, and contracts N01-CN-55424 and N01-PC-35137 from the National Cancer Institute, NIH, Department of Health and Human Services. UCI study was supported by the National Institutes of Health, National Cancer Institute grants CA-58860, CA-92044 and the Lon V Smith Foundation grant LVS-39420. The UKOPS study is funded by the OAK Foundation. Some of this work was undertaken at UCLH/UCL who received a proportion of funding from the Department of Health's NIHR Biomedical Research Centre funding scheme.

REFERENCES

1. The Wellcome Trust Case Control Consortium (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature*, **447**, 661–678.
2. Eeles, R.A., Kote-Jarai, Z., Giles, G.G., Olama, A.A., Guy, M., Jugurnauth, S.K., Mulholland, S., Leongamornlert, D.A., Edwards, S.M.,

- Morrison, J. *et al.* (2008) Multiple newly identified loci associated with prostate cancer susceptibility. *Nat. Genet.*, **40**, 316–321.
3. Gudmundsson, J., Sulem, P., Steinthorsdottir, V., Bergthorsson, J.T., Thorleifsson, G., Manolescu, A., Rafnar, T., Gudbjartsson, D., Agnarsson, B.A., Baker, A. *et al.* (2007) Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. *Nat. Genet.*, **39**, 977–983.
 4. Easton, D.F. and Eeles, R.A. (2008) Genome-wide association studies in cancer. *Hum. Mol. Genet.*, **17**, R109–R115.
 5. Pharoah, P.D. and Ponder, B.A. (2002) The genetics of ovarian cancer. *Best Pract. Res. Clin. Obstet. Gynaecol.*, **16**, 449–468.
 6. Ghousaini, M., Song, H., Koessler, T., Al Olama, A.A., Kote-Jarai, Z., Driver, K.E., Pooley, K.A., Ramus, S.J., Kjaer, S.K., Hogdall, E. *et al.* (2008) Multiple Loci with different cancer specificities within the 8q24 gene desert. *J. Natl Cancer Inst.*, **100**, 962–966.
 7. Easton, D.F., Pooley, K.A., Dunning, A.M., Pharoah, P.D., Thompson, D., Ballinger, D.G., Struwing, J.P., Morrison, J., Field, H., Luben, R. *et al.* (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. *Nature*, **447**, 1087–1093.
 8. Ioannidis, J.P., Ntzani, E.E., Trikalinos, T.A. and Contopoulos-Ioannidis, D.G. (2001) Replication validity of genetic association studies. *Nat. Genet.*, **29**, 306–309.
 9. Lohmueller, K.E., Pearce, C.L., Pike, M., Lander, E.S. and Hirschhorn, J.N. (2003) Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. *Nat. Genet.*, **33**, 177–182.
 10. Colhoun, H.M., McKeigue, P.M. and Davey, S.G. (2003) Problems of reporting genetic associations with complex outcomes. *Lancet*, **361**, 865–872.
 11. Wacholder, S., Chanock, S., Garcia-Closas, M., El Ghormli, L. and Rothman, N. (2004) Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. *J. Natl Cancer Inst.*, **96**, 434–442.
 12. Missler, M. and Sudhof, T.C. (1998) Neurexophilins form a conserved family of neuropeptide-like glycoproteins. *J. Neurosci.*, **18**, 3630–3638.
 13. Gates, M.A., Tworoger, S.S., Terry, K.L., De Vivo, I., Hunter, D.J., Hankinson, S.E. and Cramer, D.W. (2008) Breast cancer susceptibility alleles and ovarian cancer risk in 2 study populations. *Int. J. Cancer*, **124**, 729–733.
 14. Gayther, S.A., Song, H., Ramus, S.J., Kjaer, S.K., Whittemore, A.S., Quaye, L., Tyrer, J., Shadforth, D., Hogdall, E., Hogdall, C. *et al.* (2007) Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. *Cancer Res.*, **67**, 3027–3035.
 15. Ramus, S.J., Vierkant, R.A., Johnatty, S.E., Pike, M.C., Van Den Berg, D.J., Wu, A.H., Pearce, C.L., Menon, U., Gentry-Maharaj, A., Gayther, S.A. *et al.* (2008) Consortium analysis of 7 candidate SNPs for ovarian cancer. *Int. J. Cancer.*, **123**, 380–388.
 16. Rossing, M.A., Cushing-Haugen, K.L., Wicklund, K.G., Doherty, J.A. and Weiss, N.S. (2007) Menopausal hormone therapy and risk of epithelial ovarian cancer. *Cancer Epidemiol. Biomarkers Prev.*, **16**, 2548–2556.